FDA commish: First Amendment DTC defense airtight

Share this article:
FDA commissioner Andrew von Eschenbach issued a staunch First Amendment defense of DTC advertising at last week’s Center for Medicine in the Public Interest conference in Washington, DC. Asked his view on the controversy over DTC and the prospects of legislative tinkering with advertising regulation, von Eschenbach said: “As with any particular entity, whether an organization or individual, there is a right to free speech and an ability under the Constitution to free expression. We need to make sure the content is factual and accurate. FDA has role in making sure the public is continuing to get correct information.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.